Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03722927 · ClinicalTrials.gov registry record · Phase 4
The Use Of Liposomal Bupivacaine For Pain Control
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03722927 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 3 participants.
The verdict
NCT03722927, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how well the local anesthetic, liposomal bupivacaine, controls postoperative pain after mastectomy and breast reconstruction.
Interventions
- DRUG Bupivacaine
- DRUG Liposomal Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03722927
The ClinicalTrials.gov registry entry for NCT03722927 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT03722927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03722927 about?
NCT03722927 is a clinical study titled "The Use Of Liposomal Bupivacaine For Pain Control". The purpose of this research study is to determine how well the local anesthetic, liposomal bupivacaine, controls postoperative pain after mastectomy and breast reconstruction.
What is the current status of trial NCT03722927?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-06-14. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT03722927?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT03722927?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.